

Appl. No. 10/801,910  
Amdt. Dated September 7, 2005  
Reply to Office Action of July 05, 2005

### REMARKS

The undersigned would like to thank Examiner Seaman for the courtesy of the telephone interview on September 7, 2005, in which the status of claim 15 was clarified. To place the case in condition for allowance, it was agreed that claims 10, 11 and 14 would be canceled and claim 1 would be amended as described in detail below.


### REJECTION UNDER 35 USC 102

Claim 1 was rejected under 35 USC 102(b) as being anticipated by Al-Kindy. Claims 1 and 12-13 were rejected under 35 USC 102(b) as being anticipated by Mandour. It is respectfully submitted that this rejection is moot in view of the amendment to claim 1. Claim 1 was amended to delete hydrogen as a possible substituent at the 4-position of the quinoline/chromene nucleus (i.e. R<sup>1</sup>). Claim 1 is now limited to quinoline and chromene derivatives that are substituted at the 4-position with an optionally substituted alkyl or alkoxy moiety.


Al-Kindy and Mandour each disclose chromene derivatives that are unsubstituted at the 4-position (i.e. R<sup>1</sup>=H). Thus, neither Al-Kindy nor Mandour anticipate claim 1 as currently amended.

As we discussed during the telephone interview, the discussion above is equally relevant to claim 15. All of the individual species encompassed by this claim are substituted at the 4-position.

It is respectfully submitted that the claims are in condition for allowance. If any further amendments are required to place the case in condition for allowance, the undersigned invites a phone call to discuss any such amendment. Withdrawal of the rejections of record and reconsideration is respectfully requested.

  
Date  
Pfizer Inc.  
Patent Department  
2800 Plymouth Road  
Ann Arbor, MI 48105  
(734) 622-1705

Respectfully submitted,

  
J. Michael Dixon  
Attorney for Applicant(s)  
Reg. No. 32,410